Abstract: The present disclosure in various embodiments teaches methods of treating patients in need of treatment with a Factor Xa inhibitor, and who are also concomitantly administered verapamil.

Abstract: Techniques and technologies for cross-device task execution are described. In at least some embodiments, a system includes a processing component configured to: receive device information associated with a networked group of devices; receive user preference information indicating one or more user preferences for performing one or more tasks; receive an indication of a task to be performed; select a designated device of the networked group of devices associated with the user to perform the task based at least partially on the user preference information; and transmit the task to be performed to the designated device.

Abstract: The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.

Abstract: The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug contraindicated for concomitant administration with a strong CYP3A4 inhibitor, wherein the patient is treated with multiple doses of posaconazole, stops posaconazole treatment, and then is treated with the CYP3A4 substrate drug. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-21 after stopping posaconazole. In some embodiments, the patient is treated with or prescribed a reduced dose of the CYP3A4 substrate drug for about 2-21 after stopping posaconazole.

Abstract: The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug contraindicated for concomitant administration with a strong CYP3A4 inhibitor, wherein the patient is treated with multiple doses of posaconazole, stops posaconazole treatment, and then is treated with the CYP3A4 substrate drug. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-21 after stopping posaconazole. In some embodiments, the patient is treated with or prescribed a reduced dose of the CYP3A4 substrate drug for about 2-21 after stopping posaconazole.

Abstract: The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug contraindicated for concomitant administration with a strong CYP3A4 inhibitor, wherein the patient is treated with multiple doses of posaconazole, stops posaconazole treatment, and then is treated with the CYP3A4 substrate drug. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 5-21 after stopping posaconazole. In some embodiments, the patient is treated with or prescribed a reduced dose of the CYP3A4 substrate drug for about 5-21 after stopping posaconazole.

Abstract: The present disclosure in various embodiments teaches methods of treating patients in need of treatment with a Factor Xa inhibitor, and who are also concomitantly administered verapamil.

Abstract: The present disclosure relates to methods of transitioning patients or obese patients being treated with vortioxetine to treatment with a monoamine oxidase inhibitor (MAOI). The methods provided include delaying administration of the MAOI for certain time periods after stopping administration of vortioxetine. The patients or obese patients possess various capabilities of metabolizing vortioxetine. The current disclosure also includes methods of switching patients to a MAOI intended to treat psychiatric disorders while being treated with vortioxetine. The methods disclosed further comprise determining vortioxetine plasma clearance and washout time for patients with different body fat status and/or different CYP2D6 metabolizer status.

Abstract: The present disclosure relates to methods of transitioning patients or obese patients being treated with vortioxetine to treatment with a monoamine oxidase inhibitor (MAOI). The methods provided include delaying administration of the MAOI for certain time periods after stopping administration of vortioxetine. The patients or obese patients possess various capabilities of metabolizing vortioxetine. The current disclosure also includes methods of switching patients to a MAOI intended to treat psychiatric disorders while being treated with vortioxetine. The methods disclosed further comprise determining vortioxetine plasma clearance and washout time for patients with different body fat status and/or different CYP2D6 metabolizer status.

Abstract: The present disclosure relates to methods of transitioning patients or obese patients being treated with vortioxetine to treatment with a monoamine oxidase inhibitor (MAOI). The methods provided include delaying administration of the MAOI for certain time periods after stopping administration of vortioxetine. The patients or obese patients possess various capabilities of metabolizing vortioxetine. The current disclosure also includes methods of switching patients to a MAOI intended to treat psychiatric disorders while being treated with vortioxetine. The methods disclosed further comprise determining vortioxetine plasma clearance and washout time for patients with different body fat status and/or different CYP2D6 metabolizer status.

Abstract: Techniques and technologies for cross-device task execution are described. In at least some embodiments, a system includes a processing component configured to: receive device information associated with a networked group of devices; receive user preference information indicating one or more user preferences for performing one or more tasks; receive an indication of a task to be performed; select a designated device of the networked group of devices associated with the user to perform the task based at least partially on the user preference information; and transmit the task to be performed to the designated device.

Abstract: The present disclosure in various embodiments teaches methods of treating patients in need of treatment with a Factor Xa inhibitor, and who are also concomitantly administered verapamil.

Abstract: In an embodiment, an internetworking device is configured with compliance proxy logic that is configured for sending, to a compliance server, a request to determine whether the command conforms to one or more compliance policies, wherein the request includes the command; receiving a compliance response from the compliance server; in response to determining whether the compliance response indicates success, executing the command only when the compliance response indicates that the command conforms to the one or more compliance policies. Thus the device can determine actively whether a proposed user command or configuration change will violate established standards or policies, before the command or change is applied to the device.

Abstract: In an embodiment, an internetworking device is configured with compliance proxy logic that is configured for sending, to a compliance server, a request to determine whether the command conforms to one or more compliance policies, wherein the request includes the command; receiving a compliance response from the compliance server; in response to determining whether the compliance response indicates success, executing the command only when the compliance response indicates that the command conforms to the one or more compliance policies. Thus the device can determine actively whether a proposed user command or configuration change will violate established standards or policies, before the command or change is applied to the device.

Abstract: In an embodiment, an internetworking device is configured with compliance proxy logic that is configured for sending, to a compliance server, a request to determine whether the command conforms to one or more compliance policies, wherein the request includes the command; receiving a compliance response from the compliance server; in response to determining whether the compliance response indicates success, executing the command only when the compliance response indicates that the command conforms to the one or more compliance policies. Thus the device can determine actively whether a proposed user command or configuration change will violate established standards or policies, before the command or change is applied to the device.

Abstract: In an embodiment, an internetworking device is configured with compliance proxy logic that is configured for sending, to a compliance server, a request to determine whether the command conforms to one or more compliance policies, wherein the request includes the command; receiving a compliance response from the compliance server; in response to determining whether the compliance response indicates success, executing the command only when the compliance response indicates that the command conforms to the one or more compliance policies. Thus the device can determine actively whether a proposed user command or configuration change will violate established standards or policies, before the command or change is applied to the device.

Abstract: A reduced feature size MOS transistor and its method of manufacture is disclosed. The present invention reduces short channel effects but does not include an LDD structure In an illustrative embodiment, a MOS transistor has a gate length of 1.25 ?m or less. The exemplary MOS transistor includes a gate oxide that forms a planar and substantially stress free interface with a substrate. As a result of the planarity and substantially stress free nature of the oxide/substrate interface, the incidence of hot carriers, and thereby, deleterious hot carrier effects are reduced. By eliminating the use of the LDD structure, fabrication complexity is reduced and series source-drain resistance is reduced resulting in improved drive current and switching speed.

Abstract: A process for forming an oxide layer includes forming a first oxide portion over a substrate at a temperature below a threshold temperature. A second oxide portion is formed under the first oxide portion at a temperature above the threshold temperature. The substrate is illustratively oxidizable silicon and the threshold temperature is the viscoelastic temperature of silicon dioxide.

Abstract: Embodiments of an investment structure that avoids the earnings and ownership dilution related to an acquisition of a target company by a subsidiary company while providing attractive capital treatment are provided herein. In one embodiment, a method for creating an investment structure includes the steps of receiving investment capital from an investor in a subsidiary company; issuing convertible preferred shares from the subsidiary company to the investor; purchasing the target company by the subsidiary company with the investment capital; receiving at least one of target company common shares or target company assets in the subsidiary company; writing a first call option from the subsidiary company on the target company common shares or target company assets to the investor; and writing a second call option on the target company shares or target company assets from the investor to the parent company that at least partially owns the subsidiary company.

Abstract: A reduced feature size MOS transistor and its method of manufacture is disclosed. The present invention reduces short channel effects but does not include an LDD structure In an illustrative embodiment, a MOS transistor has a gate length of 1.25 &mgr;m or less. The exemplary MOS transistor includes a gate oxide that forms a planar and substantially stress free interface with a substrate. As a result of the planarity and substantially stress free nature of the oxide/substrate interface, the incidence of hot carriers, and thereby, deleterious hot carrier effects are reduced. By eliminating the use of the LDD structure, fabrication complexity is reduced and series source-drain resistance is reduced resulting in improved drive current and switching speed.